about
An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers.Antiproliferative Activity and in Vivo Toxicity of Double-Point Modified Analogs of 1,25-DihydroxyergocalciferolEconomic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemiaRRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.Natural compounds for pediatric cancer treatment.Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literatureDisease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cellsSuperenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress.Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.The c-Raf modulator RRD-251 enhances nuclear c-Raf/GSK-3/VDR axis signaling and augments 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 myeloblastic leukemia cells.Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death
P2860
Q36110047-8D87B33B-E3DE-46C9-9FBB-85360374AB63Q36247475-62FAB968-1CE1-4726-B264-CBF526C87345Q37252482-529C04DF-DB97-49C9-9F83-3298B64A8B34Q37564753-3C8207BD-6E9A-4E93-80F0-F8DCD2274ACBQ37603441-4BEB135B-FCD0-4A0B-A145-5E5806110A5CQ38663897-261F2A6E-BACB-40F0-B974-71FE767513FCQ38706865-C332F46B-A9D8-464C-A3E1-426551D44A08Q39040654-3BA5287A-9C73-4471-AB35-C55ABE752A25Q41625772-35EA55B3-5F2C-4B8F-9376-5639DC4ADF0FQ46246849-58A7B89F-E044-4804-BEAB-1A6B4010EF92Q53730263-02795740-6983-4925-A414-A54D59346226Q54917620-55A9D819-F0C1-48B1-A15D-DC4512DE88C3Q54982375-C80AD0B8-4352-4064-B819-09E2EE82EF1FQ57143658-A49F05DB-D020-4D88-A373-FC3FF8961AA4
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
An ATRActive future for differentiation therapy in AML.
@en
type
label
An ATRActive future for differentiation therapy in AML.
@en
prefLabel
An ATRActive future for differentiation therapy in AML.
@en
P2860
P1433
P1476
An ATRActive future for differentiation therapy in AML.
@en
P2093
Daniel E Johnson
Robert L Redner
P2860
P304
P356
10.1016/J.BLRE.2015.01.002
P577
2015-01-21T00:00:00Z